All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
FDA grants Orphan Drug Designation to CX-01 for the treatment of AML
On 3rd January 2018, the US Food and Drug Administration (FDA) granted Orphan Drug Designation to CX-01, a low anti-coagulant heparin, for the treatment of patients with Acute Myeloid Leukemia (AML).1
Therapy for AML is associated with pancytopenia and a high failure rate due to resistant leukemia stem cells that use CXCL12/CXCR4 axis to home to marrow niches. Additionally, Platelet Factor 4 (PF4) negatively regulates bone marrow recovery after chemotherapy. CX-01 binds and inhibits PF4, thus neutralizing its activity and may also disrupt the CXCL12/CXCR4 axis, thus improving the efficacy of AML therapy.
Preliminary data from a phase IIa non-randomized trial have demonstrated that CX-01 in combination with induction chemotherapy is well-tolerated and may enhance count recovery and treatment efficacy in patients with newly diagnosed primary AML.2 Based on this finding, CX-01 is currently being explored in a phase II randomized study (NCT02873338) in combination with standard chemotherapy for patients with newly diagnosed AML. CX-01 is also being evaluated in a phase I study (NCT02995655) in combination with azacitidine for patients with relapsed or refractory AML.
References